Cancer Risk for IBD Patients on TNF-alpha Blockers?
the MPR take:
Tumor necrosis factor alpha (TNF-alpha) antagonists are indicated to treat inflammatory bowel disease (IBD) but do these agents increase the risk of cancer in IBD patients? A study published in JAMA explores this question by evaluating IBD patients from the National Patient Registry in Denmark who were exposed to TNF-alpha antagonists over a median follow-up period of 3.7 years. The use of TNF-alpha antagonists was not associated with an increased cancer risk, however, without long-term data, an increased risk cannot be completely excluded.
Design, Setting, and Participants: Nationwide register-based cohort study in Denmark, 1999-2012. Participants were 56 146 patients 15 years or older with IBD identified in the National Patient Registry, of whom 4553 (8.1%) were exposed to TNF- antagonists. Results: During 489 433 person-years of ...
READ FULL ARTICLE From Jamanetwork